| Drug General Information |
| Drug ID |
D01ZUV
|
| Former ID |
DNCL002334
|
| Drug Name |
GDC-0425
|
| Indication |
Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86]
|
Phase 1 |
[1]
|
|---|
| Company |
Genentech
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Serine/threonine-protein kinase Chk1 |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
HTLV-I infection
|
|
Viral carcinogenesis
|
|
Pathway Interaction Database
|
Fanconi anemia pathway
|
|
p73 transcription factor network
|
|
ATR signaling pathway
|
|
Circadian rhythm pathway
|
|
p53 pathway
|
|
Reactome
|
Activation of ATR in response to replication stress
|
|
Processing of DNA double-strand break ends
|
|
Presynaptic phase of homologous DNA pairing and strand exchange
|
|
G2/M DNA damage checkpoint
|
|
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
|
WikiPathways
|
DNA Damage Response
|
|
Signaling by SCF-KIT
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell Cycle
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01359696) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma. U.S. National Institutes of Health. |
|---|
| REF 2 | Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199). |
|---|
